EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Anti‐ CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study

Aung M Tun iD, Romil D Patel iD, Frederique St-Pierre, Evguenia Ouchveridze, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal iD, Priyanka A Pophali iD, Timothy S Fenske, Reem Karmali iD, Sairah Ahmed und 1 weitere

American Journal of Hematology · 2024-09 · 99 (9) · 1712-1720

DOI: 10.1002/ajh.27381 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 04.06.2024. Verfasst von Aung M Tun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antigens, CD19, Immunotherapy, Adoptive. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T‐cell (CAR‐T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B‐cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR‐T therapy in older patients with RR LBCL in the real‐world setting. Patients aged ≥65 years with RR LBCL, treated with anti‐CD19 CAR‐T therapy at 7 US institutions were included in this multicenter, retrospective, observational study. In total, 226 patients were included. Median age at infusion was 71 years (range 65–89). Best objective and complete response rates were 86% and 62%, respectively. Median follow‐up after infusion was 18.3 months. The median progression‐free survival (PFS) was 6.9 months, with 6‐ and 12‐month PFS estimates of 54% and 44%, respectively. The nonrelapse mortality (NRM) rate was 10.9% at day 180, primarily due to infections, and not impacted by the age groups. Grade ≥3 cytokine release syndrome and neurotoxicity occurred in 7% and 26%, respectively. In univariate analysis, no significant difference in PFS was seen regardless of the age groups or CAR‐T type, whereas ECOG PS ≥2, elevated LDH, bulky disease, advanced stage, extranodal involvement, the need for bridging therapy, and prior bendamustine exposure were associated with shorter PFS. These findings support the use of CAR‐T in older patients, including those aged ≥80 years. The age at CAR‐T therapy did not influence safety, survival, and NRM outcomes. Older patients should not be excluded from receiving CAR‐T therapy solely based on their chronological age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntigens, CD19Immunotherapy, AdoptiveHumansAgedAged, 80 and overMaleFemaleRetrospective StudiesReceptors, Chimeric Antigen

Substanzen

Antigens, CD19Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, Kansas, USA.
  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA.
  • Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Aung M Tun, Romil D Patel, Allison Rosenthal, Priyanka A Pophali, Reem Karmali

Zitieren

APA

Tun, A. M., Patel, R. D., St-Pierre, F., Ouchveridze, E., Niu, A., Thordardottir, T., Obasi, J., Rosenthal, A., Pophali, P. A., Fenske, T. S., Karmali, R., Ahmed, S., & Johnston, P. B. (2024). Anti‐ CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study. American Journal of Hematology, 99(9), 1712-1720. https://doi.org/10.1002/ajh.27381

Vancouver

Tun AM, Patel RD, St-Pierre F, Ouchveridze E, Niu A, Thordardottir T, et al. Anti‐ CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study. American Journal of Hematology. 2024;99(9):1712-1720. doi:10.1002/ajh.27381

BibTeX
@article{Tun2024,
  author = {Tun, Aung M and Patel, Romil D and St-Pierre, Frederique and Ouchveridze, Evguenia and Niu, Alex and Thordardottir, Thorunn and Obasi, Jennifer and Rosenthal, Allison and Pophali, Priyanka A and Fenske, Timothy S and Karmali, Reem and Ahmed, Sairah and Johnston, Patrick B},
  title = {Anti‐ CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {9},
  pages = {1712--1720},
  doi = {10.1002/ajh.27381}
}
Kostenlos starten →